Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2790)
  2. Meeting Abstract (2524)
  3. Review (119)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5687)
  2. Department of Medicine (5677)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1020)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (663)
  5. Michael Morris (587)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (196)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (121)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (413)
  4. Elsevier Science, Inc. (394)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (302)

More Publishers

Results (5687)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
    Meeting Abstract

    Attard, G.; Agarwal, N.; Graff, J. N.; Sandhu, S.; Efstathiou, E.; Özgüroğlu, M.; de Santana Gomes, A. J. P.; Vianna, K. C. M.; Luo, H.; Cheng, H. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported experience with an immunotherapy telehealth platform
    Meeting Abstract

    Daly, R. M.; Malling, C.; Dagostino, A.; Bange, E. M.; Preeshagul, I. R.; Aggen, D. H.; Carlo, M.; Chen, M. F.; Eng, J.; Ng, K. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • The role of healthcare system distrust in shaping patients' attitudes and beliefs of artificial intelligence (AI) use in oncology
    Meeting Abstract

    Santos Teles, M.; Bryl, K. L.; Chimonas, S.; Khan, A. J.; Epstein, A. S.; Daly, R. M.; Xiao, H.; Mao, J. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research
    Meeting Abstract

    Bakouny, Z.; Ahmed, N.; Fong, C.; Rahman, A.; Perea-Chamblee, T.; Pichotta, K.; Waters, M.; Fu, C.; Jeng, M. Y.; Lee, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial
    Meeting Abstract

    Daly, R. M.; Mao, J. J.; Cracchiolo, J. R.; Holland, J. C.; Huang, J.; Ebstein, A. M.; Walters, C.; Ackerman, J.; Raj, N. P.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Pilot study of an enhanced telehealth program for patients with prostate cancer
    Meeting Abstract

    Bange, E. M.; Reiner, A. S.; Liebertz, C.; Chimonas, S.; Daly, R. M.; Malling, C.; Lei, S.; Campbell, R.; Stevanovic, K.; Holland, J. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results
    Meeting Abstract

    Mar, N.; Petrylak, D. P.; Hoimes, C. J.; Rosenberg, J. E.; Flaig, T. W.; Gourdin, T. S.; Barata, P. C.; Henry, E.; Bilen, M. S.; George, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy
    Meeting Abstract

    Schwartz, L. H.; Akin, O.; Gold, S.; Deng, Y.; Lema-Dopico, A.; Chahwan, S.; Nincevic, J.; Ruby, L.; Capanu, M.; Apte, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Bedke, J.; Powles, T.; Valderrama, B. P.; Gupta, S.; Kikuchi, E.; Loriot, Y.; Galsky, M D.; Sridhar, S. S.; Yu, E. Y.; Hoffman-Censits, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save